Westie Foundation Expands Canine Clinical Trial in Response to Worldwide Interest

June 13, 2025 10:15 PM AEST | By EIN Presswire
 Westie Foundation Expands Canine Clinical Trial in Response to Worldwide Interest
Image source: EIN Presswire
HOUSTON, TX, UNITED STATES, June 13, 2025 /EINPresswire.com/ -- The Westie Foundation of America (WFA), a 501(c)3 nonprofit organization dedicated to the health and well-being of the West Highland White Terrier breed announced today the expansion of a drug study that was launched in December 2024. The drug, named 4MU, is being studied for the treatment of deadly lung scarring called Pulmonary Fibrosis (PF), sometimes also called Westie Lung Disease (WLD).

Due to increased interest and demand from around the world, the study of the investigational drug study is expanding to include West Highland White Terriers, “Westies,” and other canines suffering from the deadly lung disease and living virtually anywhere in the world.. The study was originally open to Westies only in the United States . The expanded study will now include Westies in the U.S. and worldwide and other breeds affected by PF will also be considered.

“Westie owners from around the world have been asking for their dogs to be included. We listened and now, dogs living just about anywhere are being welcomed into the study,” said Bebe Pinter, President of the Westie Foundation of America.

Background

There are currently no Pulmonary Fibrosis-specific drugs approved by the U.S. Food & Drug Administration (FDA) for use in dogs suffering from the disease. The disease causes scarring in the lungs that renders them unable to effectively transport blood oxygen, leading to lung failure and death. Two drugs were approved for PF a decade ago in humans and have been shown to slow the scarring process. Although the drugs have been used for PF in humans, neither of the drugs, pirfenidone or nintedanib, has been studied in dogs stricken by the disease. Thus, the need to explore potential new therapies for dogs with PF is important for the West Highland White Terrier breed.

Dog owners interested in having their dogs participate in the 4MU study may contact the Westie Foundation of America via email requesting their inclusion. To do so, owners should email WFA at [email protected]. To learn more about the study, visit https://westiefoundation.org/New-Pulmonary-Fibrosis-Clinical-Study.

Veterinarians are encouraged to share this important information with their canine patient owners. A paper on the subject of Pulmonary Fibrosis in domestic animals, including Westies, in particular, was published based on a 2014 Fibrosis Across Species conference of veterinary and human researchers convened by the WFA. The paper may be found at: https://pubmed.ncbi.nlm.nih.gov/30879739/

The 4MU drug study was funded by the WFA and its donor partners.
To make your tax-deductible donation to support efforts to improve the lives of Westies and other canines, donate at: https://www.westiefoundation.org/donate..

About the Westie Foundation of America: (WFA):

The Westie Foundation of America, Inc. is a non-profit organization recognized by the IRS as a 501(c)3 organization. The WFA mission is to provide financial aid and other support for the medical research to benefit the health and quality of life of West Highland White Terriers, and to develop and communicate information regarding the health care, breeding, and quality of life of Westies to Westie owners, Westie breeders, and veterinarians. To find out more about the WFA's Biobank and other efforts, or to make a tax-deductible donation, visit: https://www.WestieFoundation.org

Teresa Barnes
Westie Foundation of America
+1 303-521-4080
email us here
Visit us on social media:
Facebook

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.